GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
S

SymBio Pharmaceuticals 4582.T · JPY

Health Care · Tokyo Stock Exchange · 🇯🇵 Japan

Compare

59

-13.24%

Close of 9 Nov 2026, in JPY

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in JPY, from our data supplier.

FY2025

Revenue

¥1.31bn

FY2016FY2025

Net income

−¥4.78bn

FY2016FY2025

Free cash flow

−¥4.66bn

FY2016FY2025

Shareholders' equity

¥1.27bn

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue¥1.31bn¥2.45bn¥5.59bn¥10.01bn¥8.25bn¥2.99bn¥2.84bn¥3.84bn¥3.44bn¥2.37bn
Gross profit¥947.3m¥1.87bn¥4.41bn¥7.60bn¥5.80bn¥866.9m¥864.8m¥1.17bn¥1.03bn¥904.2m
Research and development¥3.30bn¥3.38bn¥2.64bn¥2.55bn¥1.74bn¥2.27bn¥2.44bn¥1.83bn¥3.02bn¥1.67bn
Operating income−¥4.44bn−¥3.88bn−¥811.7m¥2.01bn¥1.02bn−¥4.51bn−¥4.36bn−¥2.72bn−¥3.96bn−¥2.31bn
Net income−¥4.78bn−¥3.83bn−¥1.96bn¥1.18bn¥2.03bn−¥4.09bn−¥4.38bn−¥2.75bn−¥3.98bn−¥2.31bn
Diluted earnings per share-95.12-83.63-48.3129.8550.05-107.12-158.08-133.49-278.07-192.39

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assets¥3.87bn¥4.97bn¥8.17bn¥17.43bn¥15.18bn¥6.27bn¥5.27bn¥6.24bn¥4.25bn¥6.88bn
Cash and short-term investments¥2.88bn¥3.96bn¥6.52bn¥6.28bn¥3.86bn¥3.85bn¥3.91bn¥4.82bn¥2.96bn¥5.72bn
Total liabilities¥2.60bn¥770.8m¥8.14bn¥8.92bn¥8.43bn¥1.62bn¥873.8m¥1.34bn¥1.01bn¥1.39bn
Debt¥1.98bn————¥192.7m———¥450.0m
Shareholders' equity¥1.27bn¥4.20bn¥7.21bn¥8.51bn¥6.75bn¥4.66bn¥4.40bn¥4.90bn¥3.24bn¥5.48bn
Shares outstanding50m46m41m40m41m38m28m21m14m12m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations−¥4.58bn−¥3.42bn−¥194.7m¥1.61bn¥140.0m−¥4.12bn−¥4.35bn−¥2.32bn−¥3.82bn−¥1.96bn
Capital spending−¥82.5m−¥19.8m−¥232.8m−¥47.6m−¥63.8m−¥148.9m−¥216.5m−¥39.8m−¥57.0m−¥27.9m
Free cash flow−¥4.66bn−¥3.44bn−¥427.5m¥1.57bn¥76.2m−¥4.27bn−¥4.57bn−¥2.36bn−¥3.87bn−¥1.99bn

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Revenue¥236.5m¥233.5m¥336.8m¥324.2m¥382.6m¥264.0m¥554.5m¥613.9m
Gross profit¥165.3m¥172.8m¥251.9m¥201.9m¥291.2m¥202.4m¥428.9m¥448.1m
Operating income−¥1.29bn−¥2.34bn−¥1.10bn−¥1.19bn−¥984.9m−¥1.17bn−¥1.09bn−¥1.07bn
Net income−¥1.22bn−¥2.40bn−¥1.21bn−¥1.20bn−¥1.05bn−¥1.32bn−¥988.5m−¥1.30bn
Diluted earnings per share-15.96-31.46-24.11-23.83-20.87-26.32-21.56-28.44
Total assets¥1.91bn¥2.95bn¥3.87bn¥4.58bn¥4.14bn¥4.67bn¥4.97bn¥6.07bn
Cash and short-term investments¥977.2m¥1.90bn¥2.88bn¥3.46bn¥3.05bn¥3.61bn¥3.96bn¥5.13bn
Debt¥832.5m¥927.5m¥1.98bn¥2.34bn¥1.30bn¥700.0m——
Shareholders' equity−¥582.8m¥231.7m¥1.27bn¥1.65bn¥2.36bn¥3.40bn¥4.20bn¥5.16bn

Financial ratios

Data as of 15 Oct 2026

FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Gross margin72.4%76.4%78.9%75.9%70.3%29.0%—
Operating margin-360.1%-158.1%-14.5%19.6%12.3%-150.9%—
Net margin-365.3%-156.3%-35.1%11.8%24.6%-136.9%—
Return on equity-375.5%-91.3%-27.2%13.9%30.1%-87.8%—
Return on assets-123.5%-77.2%-24.0%6.8%13.4%-65.2%—
Free cash flow yield-179.0%-148.2%1.9%84.1%10.0%-208.1%—
Revenue growth-46.7%-56.1%-44.1%21.3%176.3%5.3%—
Earnings growth24.6%95.3%-266.4%-42.0%-149.7%-6.5%—
Current ratio2.96x6.43x8.45x4.84x4.44x3.60x—
Debt to equity1.56x0.00x—0.00x0.00x0.04x0.00x
Equity ratio32.9%84.5%88.2%48.8%44.4%74.2%—
Interest coverage-31.51x-194.38x-70.57x42.81x539.85x-167.51x—
R&D as a share of sales252.2%137.8%47.2%25.5%21.0%75.9%—
Buybacks as a share of market value-9.5%-12.8%-2.8%2.7%-6.3%-37.9%—

Growth per year

Compound annual rate

3 years5 years10 years
Revenue-49.3%-15.2%-3.8%
Operating income—-0.3%5.7%
Net income—3.1%6.1%

Average margins

Over each period

1 year3 years5 years10 years
Gross margin75.0%76.6%70.3%57.9%
Operating margin-221.2%-36.8%-34.7%-58.9%
Net margin-228.9%-48.5%-37.4%-61.1%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Price to earnings-0.9-2.4-5.121.522.9-3.5-3.8-5.7-3.1-5.1
Price to sales3.53.71.82.55.64.85.94.13.65.0

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years.

  • 4-to-1 reverse split · 26 Jun 2019

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.